Agilent wins FDA backing to move more Keytruda-linked PD-L1 testing onto Dako Omnis
Find out how Agilent’s expanded PD-L1 test approval could change automated cancer diagnostics and oncology lab workflows.
How Agilent’s PD-L1 companion diagnostic now shapes pembrolizumab access in esophageal carcinoma
FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx for esophageal and GEJ carcinoma, marking the eighth companion diagnostic indication alongside pembrolizumab. Read the analysis.